Efavirenz/emtricitabine/tenofovir

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (07:47, 22 January 2024) (edit) (undo)
 
Line 1: Line 1:
-
<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='96/960003/Cv/1'>
+
<StructureSection load='' size='340' side='right' caption='Efavirenz/emtricitabinne/tenofovir' scene='96/960003/Cv/1'>
Efavirenz/emtricitabine/tenofovir, sold under the brand name Atripla among others, is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. It contains [[efavirenz]], [[emtricitabine]], and [[Tenofovir|tenofovir disoproxil]]. It can be used by itself or together with other antiretroviral medications. Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) of HIV-1. Tenofovir is a nucleotide reverse transcriptase inhibitor of HIV-1, and it can be classified as an NtRTI. These three drugs work in combination to target the HIV reverse transcriptase protein in three ways, which reduces the virus's capacity to mutate.
Efavirenz/emtricitabine/tenofovir, sold under the brand name Atripla among others, is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. It contains [[efavirenz]], [[emtricitabine]], and [[Tenofovir|tenofovir disoproxil]]. It can be used by itself or together with other antiretroviral medications. Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) of HIV-1. Tenofovir is a nucleotide reverse transcriptase inhibitor of HIV-1, and it can be classified as an NtRTI. These three drugs work in combination to target the HIV reverse transcriptase protein in three ways, which reduces the virus's capacity to mutate.

Current revision

Efavirenz/emtricitabinne/tenofovir

Drag the structure with the mouse to rotate

References

Proteopedia Page Contributors and Editors (what is this?)

Alexander Berchansky, Michal Harel

Personal tools